Stock Analiz

GoodRx Holdings, Inc. (GDRX) financials: revenue, earnings and cash flow

Fiscal 2018–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

GoodRx’s revenue went from $250M in fiscal 2018 to $797M in fiscal 2025, growth of about 18.0% a year.

Net income in fiscal 2025 was $30M, a net margin of 3.8%; the best year in this period was 2019 with $66M.

Over the twelve months to June 30, 2026, revenue was $785M and net income $16M.

Free cash flow was $164M in fiscal 2025 and positive in 8 of the 8 years shown.

The diluted share count rose 202% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2018: $250M20182019: $388M20192020: $551M20202021: $745M20212022: $767M20222023: $750M20232024: $792M20242025: $797M2025$797M
Net income
2018: $44M20182019: $66M20192020: -$294M20202021: -$25M20212022: -$33M20222023: -$9M20232024: $16M20242025: $30M2025$30M
Free cash flow
2018: $44M20182019: $82M20192020: $111M20202021: $174M20212022: $143M20222023: $137M20232024: $183M20242025: $164M2025$164M
EPS (diluted)
2018: $0.1220182019: $0.1820192020: $-1.0720202021: $-0.0620212022: $-0.0820222023: $-0.0220232024: $0.0420242025: $0.092025$0.09

Income statement

Fiscal yearTTM20252024202320222021202020192018
Revenue$785M$797M$792M$750M$767M$745M$551M$388M$250M
Gross profit—————————
Operating income$75M$87M$66M-$27M$2M$13M-$276M$140M$77M
Net income$16M$30M$16M-$9M-$33M-$25M-$294M$66M$44M
EPS (diluted)$0.04$0.09$0.04$-0.02$-0.08$-0.06$-1.07$0.18$0.12
R&D$117M$121M$124M$136M$143M$126M$62M$29M$44M
Revenue growth—+0.6%+5.6%−2.1%+2.8%+35.4%+41.9%+55.6%—

Cash flow

Fiscal yearTTM20252024202320222021202020192018
Operating cash flow$202M$168M$184M$138M$147M$179M$131M$83M$45M
Capital spending-$4M-$4M-$1M-$1M-$4M-$5M-$21M-$1M-$804000
Free cash flow$197M$164M$183M$137M$143M$174M$111M$82M$44M
Dividends paid————————$1.3B
Buybacks$85M$216M$159M$104M$102M$0$0——
Stock-based pay$69M$77M$99M$105M$120M$160M$397M$4M$2M

Balance sheet

Fiscal yearTTM20252024202320222021202020192018
Cash—$262M$448M$672M$757M$941M$969M$26M$35M
Debt—$550M$552M$711M$725M$714M$719M$711M—
Equity—$616M$725M$762M$815M$832M$711M-$1.1B-$1.2B
Total assets—$1.4B$1.4B$1.6B$1.6B$1.6B$1.5B$387M—
Shares (diluted)348M357M392M410M413M410M275M231M118M

Margins and returns

Fiscal yearTTM20252024202320222021202020192018
Gross margin—————————
Operating margin9.5%11.0%8.3%-3.6%0.2%1.8%-50.1%36.0%31.0%
Net margin2.1%3.8%2.1%-1.2%-4.3%-3.4%-53.3%17.0%17.5%
FCF margin25.1%20.6%23.1%18.3%18.6%23.4%20.1%21.1%17.8%
ROIC—4.0%2.7%-1.5%0.1%0.7%-18.6%——
ROE—4.9%2.3%-1.2%-4.0%-3.0%-41.3%-6.1%-3.8%

Frequently asked questions

What is GoodRx’s annual revenue?

$797M in fiscal 2025 and $785M over the twelve months to June 30, 2026.

How much profit does GoodRx make?

Net income was $30M in fiscal 2025 (net margin 3.8%).

Is GoodRx’s revenue growing?

Yes: revenue rose 0.6% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.